Clinical Observision of Semimonthly Regimen for Paclitaxel Combined with 5-fluorouracil/leucovorin 48-hour Continuouse Infusion in Treatment of Advanced Breast Cancer Which Resistence CAF Regimen / 医学研究杂志

Objective To study the clinical application value of advanced breast cancer which resistence CAF regimen,treated with semimonthly regimen for paclitaxel combined with 5-fluorouracil/leucovorin 48-hour continuouse infusion.Methods 80 paients with CAF-regimen-resistant ABC were treated with paclitaxel combined with 5-fluorouracil/leucovorin continuouse infusion,paclitaxel 95mg/m2,d_1,LV 200mg,d_1,5-fluorouracil 3g/m2,continuouse infusion for 48 hours with infusion pump.every cycle lasted 2 weeks,at least 4 cycles.Results Of 80 patients,there were 9 complete and 26 partial responses,32 cases remained stable and 13 progressive.The overall response rate of 43.8%.The median time to progression was 8 months.The median survival time was 16.7 months,the patients with soft tissue,lung,pleura,bone,liver obtained response rat was 46.7%(21/45),38.5%(5/13),31.3%(5/16),40%(4/10),20%(2/10).Conclusions semimonthly regimen for paclitaxel combined with 5-fluorouracil/leucovorin 48-hour continuouse infusion is effective and acceptable toxicity,it could be considered as one of the standard chemotherapy for advanced breast cancer which resistence CAF regimen.

Development of Chemotherapy in Colorectal Cancer / 中国癌症杂志

Chemotherapy has been one of the main treatments for colorectal cancer.5-fluorouracil combined with leucoverin has been the standard regimen of treatment in colorectal cancer since 1990,although its effectiveness is still unsatisfactory.Alteration in method of administration of the drug from injection to continuous infusion has been proved to improve its effects and reduce toxicities.Recently single oral capectiabine has been shown to be at least equivalent to one of the established adjuvant 5-FU/LV regimens in terms of both disease-free and overall survival and superior with respect to toxicity and resource utilization. Active new agents in advanced colorectal cancer have been used as neo-adjuvant treatment.Addition of oxalipilatin to 5-FU/LV showed a survival advantage compared to standard 5-Fu in stage Ⅲ colon cancer as the disease-free survival at 3 years is superior for the combined arm.This end point has been shown to be a good surrogate marker for overall survival at 5 years in adjuvant treatment programs for colon cancer.The neoadjuvant therapy combining capecitabine with radiation in the treatment of locally advanced low rectal cancer has showed a high rate of down-staging of the lesions and low local recurrence without disease progress.Chemotherapy has played a more and more important role in the multidisciplinary treatment of colorectal cancer.[